NMS – Real vaqt narxi. Valyuta: USD
15.38
-0.29 (-1.85%)
Yopilishda: Mar 27, 2026, 4:00 PM EDT
14.50
-0.88 (-5.72%)
Bozordan keyin: Mar 27, 2026, 7:35 PM EDT
Monte Rosa Therapeutics, Inc. — klinik bosqichdagi biotexnologiya kompaniyasi bo'lib, terapevtik jihatdan muhim oqsillarni tanlab yo'q qilish uchun organizmning tabiiy mexanizmlaridan foydalanadigan yangi kichik molekulali aniq dori vositalarini ishlab chiqish bilan shug'ullanadi. Kompaniya og'iz orqali yuboriladigan molekulyar yopishtiruvchi degraderlarni (MGD) ishlab chiqadi, masalan, MYC-driven o'smalarini davolash uchun MRT-2359; nevrologik va tizimli otoimmün va yallig'lanish kasalliklarini davolash uchun MRT-6160; va IL-1α, IL-1β va IL-18 tomonidan qo'zg'atilgan yallig'lanish kasalliklarini, shuningdek, shikastlanish bilan bog'liq molekulyar naqshlarni davolash uchun MRT-8102. Bundan tashqari, u tuxumdon, endometriy, oshqozon va ko'krak bezi saratoni kabi ko'plab saraton turlarini davolash uchun CDK2ni ishlab chiqadi. Shuningdek, uning pipeline'ida immunologiya va yallig'lanish ko'rsatkichlari, onkologiya, yurak-qon tomirlari, metabolik va genetik kasalliklar bo'yicha dasturlar mavjud. Kompaniya, shuningdek, QuEENni, o'zining maqsadga yo'naltirilgan MGD kashfiyot va ishlab chiqish yondashuvini va MGD mahsulot nomzodlarining ratsional dizaynini amalga oshirish uchun kashfiyot mexanizmini ishlab chiqadi. U F. Hoffmann-La Roche Ltd. va Novartis bilan strategik hamkorlik va litsenziyalash shartnomasiga ega. Kompaniya 2019-yilda tashkil etilgan va Massachusets shtatining Boston shahrida joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. John C. Castle Ph.D. | Chief Data & Information Officer |
| Dr. Markus Warmuth M.D. | President, CEO & Director |
| Dr. Sharon Townson Ph.D. | Chief Scientific Officer |
| Mr. Andrew Funderburk | Chief Investor Relations and Strategy Officer |
| Mr. Filip Janku M.D., Ph.D. | Chief Medical Officer |
| Mr. Magnus Walter DPHIL | Chief Technology Officer |
| Mr. Philip Nickson J.D., Ph.D. | Chief Business & Legal Officer |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-03-17 | S-8 | glue-20260317.htm |
| 2026-01-09 | 8-K | d36015d8k.htm |
| 2026-01-07 | 8-K | glue-20260107.htm |
| 2025-12-16 | 8-K | glue-20251216.htm |
| 2025-11-06 | 10-Q | glue-20250930.htm |
| 2025-09-15 | 8-K | glue-20250915.htm |
| 2025-08-07 | 8-K | glue-20250807.htm |
| 2025-07-22 | CORRESP | filename1.htm |
| 2025-06-13 | 8-K | glue-20250613.htm |
| 2025-05-08 | 10-Q | glue-20250331.htm |
| Ms. Jennifer Champoux |
| Chief Operating Officer |